Introducing Aztreonam The First Monobactam Antibiotic, A Suitable Substitution for the Aminoglycosides

Abstract

Aztreonam (Azactam) for injection, squibb) is the first member of a new and unique class of beta - lactam antibiotics designated by researchers at the Squibb Institute for Medical Research as monobactams (monocyclic bacterially produced beta - lactam antibiotics).
In this research, for the first time, antimicrobial spectrum of aztrenoam was determined by Disk - Agar Diffusion (250 spp.) and Macrodilution Broth Methods (150 Spp.)
We also compared this antibiotic with two routine aminoglycoside antibiotics (Amikacin, Gentamicin) in Iran. The most active antibiotic in our study was aztreonam which had MIC50 & MIC90 of 4 & 32 ^g/ml specifically against Pseudomonas aeruginosa.
This rate for the other aerobic gram - negative bacteria (E. coli, Kleb. pneumoniae, Proteus mirabilis, enterobacter spp., Shigella Spp. and Salmonella Spp.) was less than 0.5 & 4 g/ml respectively.
Aztreonam's MIC90 for kleb pneumoniae was 8/jg/mI our results were Correlated to the other studies
All aerobic gram - negative bacteria has been obtained from the Qhaem's Medical Center in Mashhad - IRAN.
The results of Disk - Agar Diffusion Method determines that all bacteria were 100% susceptible against aztreonam except Pseudomonas aeruginosa with 83% susceptibility.